Proposed changes to how the military acquires and tests weapons expose taxpayers to more wasteful spending while undermining ...
Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca's IMFINZI® (durvalumab) to BCG induction and maintenance therapy demonstrated a statistically ...
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈